Scholarlink

Introduction <p>The genes encoding RUNX1 and its binding partner CBFβ are recurrently reported to be mutated in breast cancer, a major cause of mortality in women worldwide. However, the functional role for these proteins remains unproven.</p> Methods <p>The putative tumour suppressor role of <i>Runx1</i> was investigated in genetic mouse models of breast cancer. Stem cell assays, immunohistochemistry and RNAseq analyses were applied to study biological and molecular mechanisms.</p> Results <p><i>Runx1</i> loss of function leads to accelerated disease onset and tumour development in breast cancer models. Combined deletion of <i>Runx1</i> and <i>Runx2</i> further resulted in mammary cells becoming exquisitely sensitive to WNT-driven transformation, with expedited emergence of multiple tumours. <i>Runx1</i> ablation induces a stem cell-like phenotype in mammary epithelial cells, whilst transcriptomic analysis demonstrated activation of multiple oncogenic pathways, especially when <i>Runx2</i> was co-deleted. Altered <i>Runx</i> expression in the mammary epithelium also drove alterations in the tumour immune microenvironment, with changes to neutrophil and macrophage populations.</p> Conclusions <p><i>Runx1</i> restricts some forms of breast cancer and inhibits the full oncogenic potential of aberrant WNT signalling. Combined <i>Runx1</i> and <i>Runx2</i> loss dramatically accelerates disease progression suggesting that <i>Runx2</i> can substitute for <i>Runx1</i> in dampening the oncogenic effects of WNT signalling.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Runx1 and Runx2 act in concert to suppress Wnt/β-catenin-driven mammary tumourigenesis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Alessandra I. Riggio,
  • Kerri Sweeney,
  • Robin Shaw,
  • Amy Lawlor,
  • Adiba Khan,
  • Nicola Ferrari,
  • Jayanthi Anand,
  • Laura CA Galbraith,
  • Kathryn Gilroy,
  • Courtney Bull,
  • Alex L. Young,
  • Dimitris Athineos,
  • Holly Hall,
  • Farah Ghaffar,
  • Mark Hughes,
  • Claire A. Mitchell,
  • Louise Mitchell,
  • Colin Nixon,
  • Peter D. Adams,
  • Edward W. Roberts,
  • Crispin J. Miller,
  • Philip D. Dunne,
  • Kirsteen J. Campbell,
  • Ewan R. Cameron,
  • Karen Blyth

摘要

Introduction

The genes encoding RUNX1 and its binding partner CBFβ are recurrently reported to be mutated in breast cancer, a major cause of mortality in women worldwide. However, the functional role for these proteins remains unproven.

Methods

The putative tumour suppressor role of Runx1 was investigated in genetic mouse models of breast cancer. Stem cell assays, immunohistochemistry and RNAseq analyses were applied to study biological and molecular mechanisms.

Results

Runx1 loss of function leads to accelerated disease onset and tumour development in breast cancer models. Combined deletion of Runx1 and Runx2 further resulted in mammary cells becoming exquisitely sensitive to WNT-driven transformation, with expedited emergence of multiple tumours. Runx1 ablation induces a stem cell-like phenotype in mammary epithelial cells, whilst transcriptomic analysis demonstrated activation of multiple oncogenic pathways, especially when Runx2 was co-deleted. Altered Runx expression in the mammary epithelium also drove alterations in the tumour immune microenvironment, with changes to neutrophil and macrophage populations.

Conclusions

Runx1 restricts some forms of breast cancer and inhibits the full oncogenic potential of aberrant WNT signalling. Combined Runx1 and Runx2 loss dramatically accelerates disease progression suggesting that Runx2 can substitute for Runx1 in dampening the oncogenic effects of WNT signalling.